Le Lézard
Classified in: Health, Science and technology
Subject: TRI

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Results from the I-RUX Study Published in ASH2020


WEST HOLLYWOOD, Calif., Jan. 20, 2021 /PRNewswire/ -- ONCOtherapeutics and Dr. James Berenson published promising new data demonstrating that ruxolitinib (RUX), an oral JAK1/2 inhibitor, with only steroids is well tolerated and shows promising efficacy for treating heavily previously treated MM patients.

Recently published results from a Phase 1 trial for 28 heavily previously treated MM patients administered RUX, LEN and methylprednisolone (MP) demonstrated that the therapy was well tolerated and RUX overcame refractoriness to LEN and steroids (Berenson et al., Clin Cancer Res. 2020). The clinical and overall response rates were 46% and 28%, respectively, and all 12 responding patients were refractory to LEN. 

To further evaluate whether RUX and steroids without LEN demonstrate clinical activity and its tolerability in the same patient population, an ongoing Phase I trial was expanded to also include a cohort of patients treated with only this two-drug combination (NCT03110822). RUX (15mg BID) was given orally twice a day continuously and oral methylprednisolone (MP; 40 mg) every other day.

Of the 17 evaluable patients treated with RUX and steroids so far, the CBR and ORR were 53% (n=8) and 33% (n=5), respectively. The median duration of response was 4 months (range, 1-12) and median progression free survival was 5 months (range, 1-14). The combination was well tolerated with no unanticipated adverse effects.

As noted by lead investigator Dr. James R. Berenson, "Multiple myeloma patients continue to need new treatment options, especially for those who have become refractory to previously effective treatment options. Besides having a direct MM killing effect, ruxolitinib's ability to resensitize lenalidomide is a major advantage that allows clinicians to recycle drugs and recapture disease control, while maintaining the convenience of an all-oral regimen. This is an entirely new treatment approach for MM patients."

With these promising results, ONCOtherapeutics has expanded the current study to further investigate the potential of this novel two-drug combination for treating MM including those with poor kidney function.

About ONCOtherapeutics

ONCOtherapeutics is a West Hollywood-based oncology-specific Contract Research Organization (CRO) specializing in the oversight and management of clinical trials for cancer. With expertise in phase I-IV clinical trials and pharmacokinetic studies, ONCOtherapeutics offers a wide array of services that are custom tailored to meet the needs of pharmaceutical and biotech partners. Nationally recognized research oncologists and Key Opinion Leaders in oncology work in parallel with our senior level clinical research teams. ONCOtherapeutics has an excellent track record of short start-up times and adherence to enrollment and completion timelines. For more information, visit www.oncotherapeutics.com.

Contact:

Armando J. Sanchez MBA, CCRP, ACRP-CP
Vice President, Clinical Research Operations 
[email protected] 
(787) 548-9997 
www.oncotherapeutics.com

SOURCE ONCOtherapeutics


These press releases may also interest you

at 19:00
Quhuo Limited ("Quhuo," the "Company," "we" or "our"), a leading gig economy platform focusing on life services in China, today announced that it will report unaudited financial results for the second half and full year 2023 before the open of the...

at 18:56
Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:...

at 18:53
The American Council of Engineering Companies (ACEC) of California announced today the recipients of its 2024-25 Scholarship Foundation scholarships. ACEC California's Scholarship Foundation awards annual scholarships to accomplished graduate or...

at 18:50
Doma Holdings, Inc. , a leading force for innovation in the real estate industry, today announced that it has entered into a definitive agreement and plan of merger (the "transaction") with Title Resources Group ("TRG"), one of the nation's leading...

at 18:35
McorpCX, a leading customer and employee experience consultancy, and CX capabilities builder driving greater customer centricity since its founding in 2002, today announced the acquisition of UK-based myCXvision, a customer experience management...

at 18:30
The "Digital Banking - Global Strategic Business Report" has been added to  ResearchAndMarkets.com's offering. The global market for Digital Banking estimated at US$21.1 Billion in the year 2023, is projected to reach a revised size of US$53.5...



News published on and distributed by: